Document Detail

Enhanced activity of rifalazil in combination with levofloxacin, linezolid, or mupirocin against Staphylococcus aureus in vitro.
MedLine Citation:
PMID:  16883781     Owner:  NLM     Status:  MEDLINE    
Rifalazil is a potent second-generation ansamycin that kills bacterial cells by inhibiting the beta subunit of RNA polymerase. Rifalazil has several improved properties compared with rifampicin, but retains rifampicin's propensity to develop resistant mutants at high frequency. To explore strategies to overcome resistance development, we studied the effects of rifalazil in combination with several different antibiotics in an in vitro time-kill model, against both log phase and stationary phase Staphylococcus aureus cells. Experiments were carried out at high initial cell density so that the frequency and proliferation of resistant mutants could be monitored. We found that each combination was advantageous in terms of enhanced killing and the suppression of mutants, compared with each drug used alone. None of the three combinations was effective against stationary phase cells.
Marcia S Osburne; Christopher K Murphy; David M Rothstein
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of antibiotics     Volume:  59     ISSN:  0021-8820     ISO Abbreviation:  J. Antibiot.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-08-03     Completed Date:  2006-08-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0151115     Medline TA:  J Antibiot (Tokyo)     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  303-8     Citation Subset:  IM    
ActivBiotics Inc., 110 Hartwell Ave., Lexington, MA 02421, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetamides / pharmacology*
Anti-Bacterial Agents / pharmacology*
Drug Resistance, Bacterial
Drug Therapy, Combination
Microbial Sensitivity Tests
Mupirocin / pharmacology*
Ofloxacin / pharmacology*
Oxazolidinones / pharmacology*
Rifamycins / pharmacology*
Staphylococcus aureus / drug effects*,  growth & development
Reg. No./Substance:
0/Acetamides; 0/Anti-Bacterial Agents; 0/Oxazolidinones; 0/Rifamycins; 12650-69-0/Mupirocin; 129791-92-0/KRM 1648; 165800-03-3/linezolid; 82419-36-1/Ofloxacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Biosynthesis of sespendole.
Next Document:  Kettapeptin: isolation, structure elucidation and activity of a new hexadepsipeptide antibiotic from...